TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment Adherence in Pediatric Multiple Sclerosis
Brief Summary: Disease modifying therapies (DMT) are widely used for children and adolescents with MS. Nonetheless, many pediatric patients continue to relapse and therefore require changes in therapy. We designed this research study to learn more about medication use in children and adolescents with MS. We are also interested in learning what a behavioral feedback intervention can tell us about adherence to medicine. Finally, we hope this research project will inform the way we provide clinical care for children and adolescents with MS.


Options:
A: Arm Label: Behavioural Intervention/Feedback; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interview | Arm Label: Video Attention Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Video Attention Control | Intervention Type: BEHAVIORAL; Name: Motivational Interview; Assigned to Arm(s): Behavioural Intervention/Feedback | Intervention Type: OTHER; Name: Video Attention Control; Assigned to Arm(s): Video Attention Control
B: Arm Label: Multimodal Rehabilitation Program; Type: EXPERIMENTAL; Interventions: Behavioral: Multimodal Rehabilitation Program | Arm Label: Care as Usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Care as Usual | Intervention Type: BEHAVIORAL; Name: Multimodal Rehabilitation Program; Assigned to Arm(s): Multimodal Rehabilitation Program | Intervention Type: BEHAVIORAL; Name: Care as Usual; Assigned to Arm(s): Care as Usual
C: Arm Label: Chiropractic + Exercise; Type: EXPERIMENTAL; Interventions: Other: Chiropractic + Exercise | Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise | Intervention Type: OTHER; Name: Chiropractic + Exercise; Assigned to Arm(s): Chiropractic + Exercise | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise
D: Arm Label: Mindfulness Group; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness Group | Intervention Type: BEHAVIORAL; Name: Mindfulness Group; Assigned to Arm(s): Mindfulness Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of an age-and Body Weight-adjusted Rivaroxaban Regimen Compared to Standard of Care in Children With Acute Venous Thromboembolism
Brief Summary: The purpose of this study is to evaluate comparative efficacy and safety of rivaroxaban to standard of care in children with acute venous thromboembolism.


Options:
A: Arm Label: dabigatran etexilate 150 mg BID; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg twice daily (BID) | Arm Label: matching placebo twice daily (BID); Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo twice daily (BID) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg twice daily (BID); Assigned to Arm(s): dabigatran etexilate 150 mg BID | Intervention Type: DRUG; Name: matching placebo twice daily (BID); Assigned to Arm(s): matching placebo twice daily (BID)
B: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin overlapping with and followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin overlapping with and followed by VKA; Assigned to Arm(s): Enoxaparin/VKA
C: Arm Label: BAY59-7939; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Standard of Care; Type: EXPERIMENTAL; Interventions: Drug: Standard of Care | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): BAY59-7939 | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): BAY59-7939 | Intervention Type: DRUG; Name: Standard of Care; Assigned to Arm(s): Standard of Care
D: Arm Label: Dabigatran etexilate; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate intermediate dose, Drug: dabigatran etexilate low dose, Drug: dabigatran etexilate high dose | Arm Label: warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin 1mg, Drug: warfarin 5mg, Drug: warfarin 3mg | Intervention Type: DRUG; Name: warfarin 1mg; Assigned to Arm(s): warfarin | Intervention Type: DRUG; Name: dabigatran etexilate intermediate dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: dabigatran etexilate low dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 5mg; Assigned to Arm(s): warfarin | Intervention Type: DRUG; Name: dabigatran etexilate high dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 3mg; Assigned to Arm(s): warfarin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of an age-and Body Weight-adjusted Rivaroxaban Regimen Compared to Standard of Care in Children With Acute Venous Thromboembolism
Brief Summary: The purpose of this study is to evaluate comparative efficacy and safety of rivaroxaban to standard of care in children with acute venous thromboembolism.


Options:
A: Arm Label: dabigatran etexilate; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate | Arm Label: standard of care; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard of care | Intervention Type: DRUG; Name: dabigatran etexilate; Assigned to Arm(s): dabigatran etexilate | Intervention Type: DRUG; Name: standard of care; Assigned to Arm(s): standard of care
B: Arm Label: Dabigatran etexilate (150mg bid); Type: EXPERIMENTAL; Interventions: Drug: Dabigatran etexilate | Arm Label: Warfarin (INR 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR 2.0-3.0) | Intervention Type: DRUG; Name: Dabigatran etexilate; Assigned to Arm(s): Dabigatran etexilate (150mg bid)
C: Arm Label: BAY59-7939; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Standard of Care; Type: EXPERIMENTAL; Interventions: Drug: Standard of Care | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): BAY59-7939 | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): BAY59-7939 | Intervention Type: DRUG; Name: Standard of Care; Assigned to Arm(s): Standard of Care
D: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin, Drug: warfarin, Drug: Placebo for apixaban | Arm Label: Enoxaparin + Warfarin; Type: EXPERIMENTAL; Interventions: Drug: Placebo for enoxaparin, Drug: Placebo for warfarin, Drug: apixaban | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo for apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo for enoxaparin; Assigned to Arm(s): Enoxaparin + Warfarin | Intervention Type: DRUG; Name: Placebo for warfarin; Assigned to Arm(s): Enoxaparin + Warfarin | Intervention Type: DRUG; Name: apixaban; Assigned to Arm(s): Enoxaparin + Warfarin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy - HF (ATHENA-HF)
Brief Summary: The primary objective of this study is to test the hypothesis that high-dose spironolactone will lead to greater proportional reduction in NT-proBNP levels from randomization to 96 hours over standard of care.


Options:
A: Arm Label: Finerenone(BAY94-8862)[2.5mg] + Placebo; Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862), Drug: Placebo | Arm Label: Finerenone (BAY94-8862)[5mg] + Placebo; Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862), Drug: Placebo | Arm Label: Finerenone (BAY94-8862)[7.5mg] + Placebo; Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862), Drug: Placebo | Arm Label: Finerenone (BAY94-8862)[10mg] + Placebo; Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862), Drug: Placebo | Arm Label: Finerenone (BAY94-8862)[15mg] + Placebo; Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862), Drug: Placebo | Arm Label: Eplerenone [25 mg] + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Inspra (eplerenone) | Intervention Type: DRUG; Name: Finerenone (BAY94-8862); Assigned to Arm(s): Finerenone (BAY94-8862)[10mg] + Placebo, Finerenone (BAY94-8862)[15mg] + Placebo, Finerenone (BAY94-8862)[5mg] + Placebo, Finerenone (BAY94-8862)[7.5mg] + Placebo, Finerenone(BAY94-8862)[2.5mg] + Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Eplerenone [25 mg] + Placebo, Finerenone (BAY94-8862)[10mg] + Placebo, Finerenone (BAY94-8862)[15mg] + Placebo, Finerenone (BAY94-8862)[5mg] + Placebo, Finerenone (BAY94-8862)[7.5mg] + Placebo, Finerenone(BAY94-8862)[2.5mg] + Placebo | Intervention Type: DRUG; Name: Inspra (eplerenone); Assigned to Arm(s): Eplerenone [25 mg] + Placebo
B: Arm Label: Spironolactone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Spironolactone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: ACE/ARB; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Spironolactone/ARB; Type: ACTIVE_COMPARATOR; Interventions: Drug: spironolacone 25 mg tablets added to losartan | Intervention Type: DRUG; Name: spironolacone 25 mg tablets added to losartan; Assigned to Arm(s): Spironolactone/ARB
D: Arm Label: addition of spironolactone; Type: EXPERIMENTAL; Interventions: Drug: spironolactone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: spironolactone; Assigned to Arm(s): addition of spironolactone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: iChoose Kidney Decision Aid for Treatment Options Among End-Stage Renal Disease (ESRD) Patients
Brief Summary: The investigators developed iChoose Kidney -- a shared decision-making support tool accessible through iPad, iPhone, or the web -- to provide ESRD patients and their providers with a simple, standardized, easily accessible, statistically robust tool for use in the clinic to guide patient education and healthcare decision-making about treatment options of dialysis or kidney transplantation. The iChoose Kidney decision aid provides patients with estimates of their individualized 1 and 3-year risks of mortality on dialysis vs. transplantation, based on previous national data. The tool has the potential to improve communication and decision-making between patients and their healthcare providers and improve access to kidney transplantation among patients with ESRD.

This will be a two-arm, randomized study, and will be conducted at 3 large transplant centers with diverse patient populations. One group of patients will receive standard education alone during their scheduled transplant evaluation. The second group will receive the standard education as well have the provider use the iChoose Kidney aid with them. The project timeline will be a total of 24 months inclusive of enrollment, follow-up, data analysis, and outcome evaluation.

This study will assess how well the iChoose decision aid works in improving patient knowledge, preferences for treatment, and patient access to transplant. The study will also assess whether providers find the tool useful for providing ways to share information with patients about ways to treat their kidney disease.


Options:
A: Arm Label: Information; Type: EXPERIMENTAL; Interventions: Behavioral: Information | Arm Label: Information and Financial Assistance; Type: EXPERIMENTAL; Interventions: Behavioral: Information | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Information; Assigned to Arm(s): Information, Information and Financial Assistance
B: Arm Label: Facebook group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Facebook group | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Facebook group; Assigned to Arm(s): Facebook group
C: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Combination Product: VC-01™ Combination Product | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Combination Product: VC-01™ Combination Product | Intervention Type: COMBINATION_PRODUCT; Name: VC-01™ Combination Product; Assigned to Arm(s): Cohort 1, Cohort 2
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: iChoose Kidney Decision Aid; Type: EXPERIMENTAL; Interventions: Behavioral: iChoose Kidney Decision Aid | Intervention Type: BEHAVIORAL; Name: iChoose Kidney Decision Aid; Assigned to Arm(s): iChoose Kidney Decision Aid

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Folic Acid Supplementation Lowering Arsenic in a Chronic, Low-level Exposed Arsenic Population: a Randomized, Double-blind, Placebo Controlled Clinical Trial.
Brief Summary: The purpose of this study is to determine whether folic acid supplementation are effective on arsenic lowering in a chronic, low-level arsenic exposed population.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Iron (27 mg) - folic acid (600 ug) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multiple micronutrient | Intervention Type: DIETARY_SUPPLEMENT; Name: Iron (27 mg) - folic acid (600 ug); Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Multiple micronutrient; Assigned to Arm(s): 2
B: Arm Label: folic acid; Type: EXPERIMENTAL; Interventions: Drug: folic acid supplementation | Intervention Type: DRUG; Name: folic acid supplementation; Assigned to Arm(s): folic acid
C: Arm Label: Nutritional Intervention Arm; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin B12, Dietary Supplement: Folic Acid | Arm Label: Control Arm; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin B12; Assigned to Arm(s): Nutritional Intervention Arm | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Control Arm | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic Acid; Assigned to Arm(s): Nutritional Intervention Arm
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Folic Acid 400 ug; Type: EXPERIMENTAL; Interventions: Dietary Supplement: folic acid | Arm Label: Folic Acid 800 ug; Type: EXPERIMENTAL; Interventions: Dietary Supplement: folic acid | Arm Label: Creatine; Type: EXPERIMENTAL; Interventions: Dietary Supplement: creatine | Arm Label: Creatine + Folic Acid; Type: EXPERIMENTAL; Interventions: Dietary Supplement: creatine + folic acid | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: folic acid; Assigned to Arm(s): Folic Acid 400 ug | Intervention Type: DIETARY_SUPPLEMENT; Name: folic acid; Assigned to Arm(s): Folic Acid 800 ug | Intervention Type: DIETARY_SUPPLEMENT; Name: creatine; Assigned to Arm(s): Creatine | Intervention Type: DIETARY_SUPPLEMENT; Name: creatine + folic acid; Assigned to Arm(s): Creatine + Folic Acid

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Complementary Therapies Delivered Via Mobile Technologies on Surgical Patients' Reports of Anxiety, Pain, and Self-Efficacy in Healing: A Pilot Randomized Controlled Trial in Iceland
Brief Summary: The purpose of this study is to determine the effects of complementary therapies delivered via mobile technologies have a therapeutic effect on surgical patients' anxiety, pain, and self-efficacy in healing reports before, following, and at 10-day follow-up.


Options:
A: Arm Label: Audio Relaxation technique; Type: EXPERIMENTAL; Interventions: Behavioral: Audio Relaxation Technique | Arm Label: Medical Music Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Medical Music Intervention | Arm Label: Nature Therapy without Music; Type: EXPERIMENTAL; Interventions: Behavioral: Nature Therapy without Music | Arm Label: Nature Therapy with Music; Type: EXPERIMENTAL; Interventions: Behavioral: Nature Therapy with Music | Intervention Type: BEHAVIORAL; Name: Audio Relaxation Technique; Assigned to Arm(s): Audio Relaxation technique | Intervention Type: BEHAVIORAL; Name: Medical Music Intervention; Assigned to Arm(s): Medical Music Intervention | Intervention Type: BEHAVIORAL; Name: Nature Therapy without Music; Assigned to Arm(s): Nature Therapy without Music | Intervention Type: BEHAVIORAL; Name: Nature Therapy with Music; Assigned to Arm(s): Nature Therapy with Music
B: Arm Label: controls; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: cases; Type: EXPERIMENTAL; Interventions: Behavioral: mindfulness based stress reduction (MBSR) | Intervention Type: BEHAVIORAL; Name: mindfulness based stress reduction (MBSR); Assigned to Arm(s): cases
C: Arm Label: THA Physiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: THA Physiotherapy, Procedure: No physiotherapy after THA | Arm Label: No physiotherapy after THA; Type: ACTIVE_COMPARATOR; Interventions: Procedure: No physiotherapy after THA | Intervention Type: PROCEDURE; Name: THA Physiotherapy; Assigned to Arm(s): THA Physiotherapy | Intervention Type: PROCEDURE; Name: No physiotherapy after THA; Assigned to Arm(s): No physiotherapy after THA, THA Physiotherapy
D: Arm Label: usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: educational program+telephone follow up; Type: EXPERIMENTAL; Interventions: Behavioral: educational program+telephone follow up | Intervention Type: BEHAVIORAL; Name: educational program+telephone follow up; Assigned to Arm(s): educational program+telephone follow up | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): usual care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sustainability of a Multidimensional Knowledge Translation Intervention to Improve Paediatric Pain Practices and Outcomes
Brief Summary: The purpose of this research study is to evaluate the effectiveness of short refresher sessions. "Pain Practice Change Boosters" given at regular intervals to sustain improved pain process (assessment and management) and clinical outcomes (pain intensity) achieved during a 15 month knowledge translation intervention, Evidence-based Practice for Improving Quality (EPIQ), in 8 children's hospitals in Canada; and to determine the factors that affect that sustainability. The CIHR Team in Children's Pain (2006-2011) evaluated the effectiveness of the EPIQ intervention in 32 hospital units (4 units at each hospital site). 16 hospital units were allocated to the intervention group and 16 units continued with standard care. The current study focuses on the 16 hospital units that implemented the EPIQ intervention only.


Options:
A: Arm Label: control; Type: N/A; Interventions: N/A | Arm Label: sucrose; Type: N/A; Interventions: N/A | Arm Label: physical intervention; Type: N/A; Interventions: N/A | Arm Label: physical intervention and sucrose; Type: N/A; Interventions: N/A
B: Intervention Type: PROCEDURE; Name: Percutaneous Suprapubic Aspiration; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Urethral Catheterization; Assigned to Arm(s): N/A
C: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: water; Type: EXPERIMENTAL; Interventions: Other: sterile water | Arm Label: sucrose; Type: EXPERIMENTAL; Interventions: Drug: Sucrose | Arm Label: pacifier; Type: EXPERIMENTAL; Interventions: Device: Pacifier | Arm Label: water and pacifier; Type: EXPERIMENTAL; Interventions: Device: Pacifier | Arm Label: sucrose and pacifier; Type: EXPERIMENTAL; Interventions: Drug: Sucrose, Device: Pacifier | Intervention Type: DRUG; Name: Sucrose; Assigned to Arm(s): sucrose, sucrose and pacifier | Intervention Type: DEVICE; Name: Pacifier; Assigned to Arm(s): pacifier, sucrose and pacifier, water and pacifier | Intervention Type: OTHER; Name: sterile water; Assigned to Arm(s): water
D: Arm Label: Pain Practice Change Booster; Type: EXPERIMENTAL; Interventions: Behavioral: Pain Practice Change Booster Intervention | Arm Label: Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Pain Practice Change Booster Intervention; Assigned to Arm(s): Pain Practice Change Booster

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transfer Modality Research Initiative - Bangladesh
Brief Summary: This is a randomized control trial in two zones of Bangladesh (north and south). Treatment is assigned at the village level where treatments are: cash transfers (north and south); cash transfers + nutrition behavior communication change (north only); food transfers (north and south); food transfers + nutrition behavior communication change (south only); food-cash split (north and south); and controls (north and south). Within treatment localities, women living in very poor households are targeted to receive benefits for two years.


Options:
A: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Policy and Environmental Change; Type: EXPERIMENTAL; Interventions: Behavioral: Policy and Environmental Change | Intervention Type: BEHAVIORAL; Name: Policy and Environmental Change; Assigned to Arm(s): Policy and Environmental Change
B: Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy Start | Arm Label: Control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Healthy Start; Assigned to Arm(s): Intervention arm
C: Arm Label: Cash transfer; Type: EXPERIMENTAL; Interventions: Other: Cash transfer | Arm Label: Food transfer; Type: EXPERIMENTAL; Interventions: Other: Food transfer | Arm Label: Food and cash transfer; Type: EXPERIMENTAL; Interventions: Other: Food and cash transfer | Arm Label: Cash transfer + BCC; Type: EXPERIMENTAL; Interventions: Other: Cash transfer, Behavioral: Behavior Communication Change (BCC) | Arm Label: Food transfer + BCC; Type: EXPERIMENTAL; Interventions: Other: Food transfer, Behavioral: Behavior Communication Change (BCC) | Intervention Type: OTHER; Name: Cash transfer; Assigned to Arm(s): Cash transfer, Cash transfer + BCC | Intervention Type: OTHER; Name: Food transfer; Assigned to Arm(s): Food transfer, Food transfer + BCC | Intervention Type: OTHER; Name: Food and cash transfer; Assigned to Arm(s): Food and cash transfer | Intervention Type: BEHAVIORAL; Name: Behavior Communication Change (BCC); Assigned to Arm(s): Cash transfer + BCC, Food transfer + BCC
D: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Behavioral: Education, Behavioral: Problem Solving, Behavioral: Social Learning, Behavioral: Behavior Modification | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Group A, Group B | Intervention Type: BEHAVIORAL; Name: Problem Solving; Assigned to Arm(s): Group A | Intervention Type: BEHAVIORAL; Name: Social Learning; Assigned to Arm(s): Group A | Intervention Type: BEHAVIORAL; Name: Behavior Modification; Assigned to Arm(s): Group A

Answer: C